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Abstract objective To provide a broad and up-to-date picture of the effect of antiretroviral therapy (ART)
provision on population-level mortality in Southern and East Africa.
methods Data on all-cause, AIDS and non-AIDS mortality among 15–59 year olds were analysed
from demographic surveillance sites (DSS) in Karonga (Malawi), Kisesa (Tanzania), Masaka (Uganda)
and the Africa Centre (South Africa), using Poisson regression. Trends over time from up to 5 years prior
to ART roll-out, to 4–6 years afterwards, are presented, overall and by age and sex. For Masaka and
Kisesa, trends are analysed separately for HIV-negative and HIV-positive individuals. For Karonga
and the Africa Centre, trends in AIDS and non-AIDS mortality are analysed using verbal autopsy data.
results For all-cause mortality, overall rate ratios (RRs) comparing the period 2–6 years following
ART roll-out with the pre-ART period were 0.58 (5.9 vs. 10.2 deaths per 1000 person-years) in
Karonga, 0.79 (7.2 vs. 9.1 deaths per 1000 person-years) in Kisesa, 0.61 (6.7 compared with 11.0 deaths
per 1000 person-years) in Masaka and 0.79 (14.8 compared with 18.6 deaths per 1000 person-years) in
the Africa Centre DSS. The mortality decline was seen only in HIV-positive individuals ⁄AIDS mortality,
with no decline in HIV-negative individuals ⁄non-AIDS mortality. Less difference was seen in Kisesa
where ART uptake was lower.
conclusions Falls in all-cause mortality are consistent with ART uptake. The largest falls occurred
where ART provision has been decentralised or available locally, suggesting that this is important.
keywords antiretroviral therapy, mortality, sub-Saharan Africa
Introduction
Adult HIV prevalence has been high across Southern and
East Africa since the 1990s, ranging from around 6% to
over 20% (UNAIDS & WHO 2009), and recent evidence
shows that HIV incidence remains high (Stover et al.
2010). The impact of HIV on adult mortality has been
huge: for example, 63% of all deaths were attributed to
AIDS among 15–59 year olds in northern Malawi (Jahn
et al. 2008) between 2002 and 2005, around half of all
deaths in 15–44 year olds in a rural community in
Mwanza, Tanzania were because of AIDS during 1994–
1998 (Urassa et al. 2001) and 60% of all deaths were
attributable to AIDS in KwaZulu Natal, South Africa
between 2000 and 2003 (Hosegood et al. 2004).
Since about 2004, provision of antiretroviral therapy
(ART) has been rolled out in the public sector across sub-
Saharan Africa. ART has the potential to prolong and save
lives on a massive scale. Median retention in care among
individuals in ART programs in Africa after 3 years is
around 70% (Fox & Rosen 2010), and there is accumu-
lating evidence that this can translate into substantial
reductions in adult mortality at the population level
(Herbst et al. 2009; Reniers et al. 2009; Floyd et al. 2010;
Mwagomba et al. 2010; Kasamba et al. 2012; Marston
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et al. 2012). For example, in Karonga district in northern
Malawi, all-cause mortality among 15–59 year olds fell by
around 30% and mortality attributed to AIDS by around
50% during the third year of ART provision, compared
with the years immediately preceding ART roll-out
(Floyd et al. 2010). In KwaZulu Natal, among adults aged
25–49 years old, mortality attributed to AIDS fell by
around 25% averaged over the first 3 years of ART roll-
out (Herbst et al. 2009), and in Masaka district, Uganda
all-cause mortality among 15–59 year olds fell by an
average of around 40% between 1 and 5 years after the
start of free ART provision (Kasamba et al. 2012).
The population-level effect of ART provision on adult
mortality will vary across settings, depending on HIV
prevalence, access to ART and retention in care after
starting treatment. In this paper, we synthesise evidence
across four demographic surveillance sites (DSS), in
Malawi, South Africa, Tanzania and Uganda. Our aim is to
provide a broad and up-to-date picture of the effect of ART
on population-level mortality in Southern and East Africa,
using the same methods of analysis across sites to enable
fair comparison. We analyse time trends in all-cause adult
mortality, overall and also stratified according to an
individual’s HIV status for two sites (Masaka and Kisesa)
with high coverage of HIV testing in the DSS both before
and following ART roll-out. We also analyse AIDS and
non-AIDS mortality for two sites (Karonga and the Africa
Centre), which have verbal autopsy data available for
analysis for both the time period immediately preceding
ART roll-out and subsequently. We interpret the findings
in the context of ART uptake and retention in treatment
programmes in each site.
Methods
Sites and settings
The Karonga DSS is located in rural northern Malawi,
was established with a baseline census in 2002 and has a
total population of around 33 500 (Jahn et al. 2007).
Most of the population are subsistence farmers, and adult
HIV prevalence is approximately 10% (McGrath et al.
2007). The Kisesa DSS and cohort study is located in
north-west Tanzania, was established in 1994 and has a
total population of around 30 000 (Mwaluko et al.
2003). Most of the population are subsistence farmers,
but petty trading is also an important income source, and
adult HIV prevalence is around 6% (Zaba et al. 2010).
The Masaka DSS is located in rural south-west Uganda,
was established in 1989, has a total population of around
20 000 (Mbulaiteye et al. 2002), and an adult HIV
prevalence of 7–8% (Shafer et al. 2008). The Africa
Centre DSS is in rural KwaZulu Natal, South Africa, and
was established in 2000, when it had a total population
of around 90 000 (Tanser et al. 2008). Adult HIV
prevalence was around 22% among 15–54 year olds in
2004 (Welz et al. 2007).
Demographic surveillance
In Karonga and Masaka DSS, information on births and
deaths is collected monthly, and in- and out-migrations are
updated during an annual re-census (Jahn et al. 2007;
Kasamba et al. 2012). In Kisesa and the Africa Centre DSS,
data on births, deaths and migrations are collected at
6-month intervals (Mwaluko et al. 2003; Tanser et al. 2008).
HIV testing as part of the research programme, Kisesa and
Masaka
In Kisesa, sero-surveys have been conducted approximately
every 3 years, since 1994, with informed consent. Six
sero-surveys have been completed, with participation rates of
63–74%, and all individuals who are resident in the DSS
areaandaged15 yearsormoreare eligible toparticipate. HIV
testing is carried out at a temporary clinic established in the
centre of each village in the DSS; since 2003, all individuals
who wish to learn their HIV status have been referred to a
counsellor who is a member of the sero-survey team.
In Masaka, annual sero-surveys among individuals aged
13 or more years old started in 1989, and are conducted at
people’s homes. Individuals can obtain the result of the
HIV test several weeks later, from a local VCT centre.
Around 60–65% of all eligible individuals consent to HIV
testing in each sero-survey.
ART provision, regimens, eligibility and uptake
A full description of methods used to estimate ART need
and ART uptake in the four DSS are provided elsewhere in
this supplement (Wringe et al. 2012; Zaba et al. 2012),
and we include a brief summary of key findings here. In all
sites, ART was provided through the public health system
and was free at the point of care.
In Karonga, public-sector provision of ART began in the
district in June 2005 at a clinic about 200 km from the DSS
area, and within the DSS area in October 2006. By 2008,
ART uptake was estimated to be approximately 60% of
those in need (Wringe et al. 2012). The first-line ART
regimen was a fixed-dose combination tablet of stavudine,
lamivudine and nevirapine, taken twice daily, for the time
period covered by our analysis. Individuals were eligible
to start ART if they were in WHO clinical stage 3 or 4, or
had a CD4 count of <250 cells ⁄mm3.
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In Kisesa, free ART provision to individuals living in the
DSS area started in April 2005. Up to 2008, treatment was
provided from a regional referral hospital 20 km away
in Mwanza City. Decentralisation of ART provision has
proceeded relatively slowly, and ART uptake was
estimated as around 3% of those in need in 2007, and very
low for both men and women (Wringe et al. 2012). The
first-line ART regimen was a fixed-dose combination tablet
of stavudine, lamivudine and nevirapine during the period
up to 2007. Individuals were eligible to start ART if they
had a CD4 count of <250 cells ⁄mm3 or were in WHO
clinical stage 4, and ⁄or had particular WHO clinical stage
3 conditions.
In Masaka DSS, free ART provision within the DSS
began in January 2004, provided from a single clinic. By
2008, ART uptake was estimated to be around 70% of
those in need (Wringe et al. 2012). Individuals were
eligible to start ART if they had a CD4 cell count of
<200 cells ⁄mm3, WHO clinical stage 4 disease or
advanced stage 3 disease with persistent or recurrent oral
thrush and invasive bacterial infections regardless of
CD4 count. First-line treatment consists of a combination
of zidovudine, lamivudine and nevirapine.
In the Africa Centre DSS, ART is provided in the public
sector through a decentralised network of primary health
care clinics (Herbst et al. 2009), and by 2009, there were
six clinics providing ART in the DSS area. In 2008, 21% of
all HIV-infected adults were receiving ART (Cooke et al.
2010), while a study based on CD4 counts in the people
participating in HIV testing in the surveillance showed that
75% of those needing ART received the treatment in 2010
(Malaza et al. 2011). The first-line ART regimen is
stavudine and lamivudine, combined with either nevirapine
or efavirenz. Individuals were eligible to start ART if they
had a CD4 count of <200 cells ⁄mm3 and ⁄or were in WHO
clinical stage 4.
Verbal autopsies
In Karonga and the Africa Centre, verbal autopsies have
been conducted for all deaths since the establishment of the
DSS, and the way in which verbal autopsies are performed
is described fully elsewhere (Hosegood et al. 2004; Floyd
et al. 2010). AIDS and non-AIDS deaths can be
distinguished by the reviewing clinician, and in the analyses
presented here, deaths attributed to TB ⁄AIDS are included
as AIDS mortality.
Statistical analysis
Analysis covered the time period 5 years prior to the start
of public-sector ART provision in the study district, and
4–6 years afterwards (Table 1). Analyses were restricted to
15–59 year olds, because in the pre-ART period, a very
low proportion of deaths in older individuals were attrib-
utable to AIDS.
For each site, person-time was calculated from the date
an individual was first resident in the DSS until the
earliest of date of death, out-migration from the study area
or end of the follow-up period. Person-time was left-
truncated if it was more than 5 years prior to the roll-out
of free ART. If an individual left and later returned to
live in the DSS area, then the time that they were away was
not counted towards their person-time, except if they
missed only one round of demographic surveillance.
For each site, calendar time was divided into three time
periods (Table 1): pre-ART roll-out in the district, early in
the time period following ART roll-out (denoted ART
period 1) and later in the time period following ART
roll-out (denoted ART period 2). Area of residence was
categorised into one of ‘remote rural’, ‘roadside
rural ⁄peri-urban’ and ‘urban’. For each site, Poisson
regression was used to calculate rate ratios (RRs) for the
effect of time period, overall and stratified by age, sex and
area of residence.
In Kisesa and Masaka, all available data on HIV test
results were used to calculate the date of an individual’s
first HIV-negative, last HIV-negative and first HIV-positive
test result. Person-time before the first HIV test result was
not included in analysis, and for individuals who were
known to have sero-converted, their sero-conversion date
was calculated as halfway between their last HIV-negative
and first HIV-positive test result. For individuals with at
least one HIV-negative test result, who were not known to
Table 1 Calendar time periods included in analysis of adult mortality
Kisesa Masaka Africa Centre Karonga
Pre-ART Jan 2000 End Dec 2004 Jan 1999 End Dec 2003 End Dec 2003 Aug 2002 End June 2005
ART period 1 Jan 2005 End Dec 2005 Jan 2004 End Dec 2005 Jan 2004 End Dec 2005 July 2005 End Sept 2006
ART period 2 Jan 2006 Jan 2010 Jan 2006 End Dec 2009 Jan 2006 End Dec 2009 Oct 2006* End Dec 2009
ART, antiretroviral therapy; DSS, demographic surveillance sites.
*A clinic providing ART opened in the DSS area at the end of September 2006.
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have sero-converted, the analysis included their person-
time in the HIV-negative population up to 5 years after the
last recorded HIV-negative test result.
For Karonga and the Africa Centre DSS, for analysis of
AIDS mortality, deaths because of non-AIDS and non-
specifiable causes were censored; for analysis of non-AIDS
mortality, deaths because of AIDS were censored (Herbst
et al. 2009; Floyd et al. 2010).
Results
All-cause mortality among 15–59 year olds, overall
Overall, all-cause mortality fell progressively following
ART roll-out in Karonga, Kisesa and Masaka, and by ART
period 2 in the Africa Centre DSS (Table 2). This overall
trend was seen for both men and women and for all three
age groups. In Karonga and Kisesa, the fall in mortality
was smaller in remote rural areas, while in the Africa
Centre DSS, there was no evidence of a fall in mortality in
urban areas.
The overall rate ratio, comparing ART period 2 with
the pre-ART period, was 0.58 (5.9 compared with 10.2
deaths per 1000 person-years, 95% CI for the RR [0.50–
0.69], P < 0.001) in Karonga, 0.79 (7.2 compared with
9.1 deaths per 1000 person-years, 95% CI for the RR
[0.67–0.91], P = 0.002) in Kisesa, 0.61 (6.7 compared
with 11.0 deaths per 1000 person-years, 95% CI for the
RR [0.52–0.72], P < 0.001) in Masaka and 0.79 (14.8
compared with 18.6 deaths per 1000 person-years, 95%
CI for the RR [0.75–0.84], P < 0.001) in the Africa
Centre DSS. These overall rate ratios changed little when
adjusted for age, sex and area of residence (data not
shown).
All-cause mortality among 15–59 year olds, stratified by
individual HIV status (Kisesa and Masaka)
In Masaka, the fall in all-cause mortality was dramatic
among HIV-positive individuals, with little change among
HIV-negative individuals (P < 0.001 for interaction,
Table 3a). The dramatic falls in mortality among HIV-
positive individuals were seen for both men and women,
and in each age group. The rate ratio in HIV-positive
individuals, comparing ART period 2 with the pre-ART
period, was 0.35 (37.8 deaths compared with 108.2
deaths per 1000 person-years). The patterns by HIV
status and age were similar when carried out separately
for men and women to those seen overall (data not
shown).
In Kisesa, mortality fell in the HIV-positive individuals
with no change in mortality in the HIV-negative individ-
uals (P < 0.001 for interaction). But the fall in the HIV-
positive individuals was not as dramatic as in Masaka, and
the difference in trends between HIV-positive and HIV-
negative individuals was only seen in men (P < 0.001), not
in women (P = 0.47) (Table 3b). There was weak evidence
that mortality among HIV-negative men increased.
AIDS and non-AIDS mortality among 15–59 year olds
(Karonga and Africa Centre)
In Karonga, AIDS mortality fell dramatically following
ART roll-out, overall, in men and women, in all age groups
and in remote rural and roadside areas (Table 4a). In ART
period 2, the rate ratio compared with the pre-ART time
period was 0.36 (2.3 compared with 6.4 deaths per 1000
person-years). There was little change over time in non-
AIDS mortality (3.6 compared with 3.8 deaths per 1000
person-years in ART period 2 and the pre-ART period,
respectively).
In the Africa Centre DSS, AIDS mortality fell overall, for
men and women, among 15–44 year olds but not among
older individuals, and in rural and peri-urban but not
urban areas (Table 4b). Overall, the rate ratio comparing
ART period 2 with the pre-ART period was 0.73 (9.9
compared with 13.6 deaths per 1000 person-years). Non-
AIDS mortality fluctuated, but there was little evidence of a
trend over time (Table 4b).
Discussion
There is strong evidence of a fall in all-cause mortality
among 15–59 year olds after ART roll-out in all four
DSS included in this study. In Karonga and Masaka
DSS, the fall was around 40%, and in Kisesa and the
Africa Centre DSS around 20%, during the period
2–5 years following ART roll-out. For three sites,
supporting evidence that this fall is largely attributable
to ART provision comes from analysis of AIDS and
non-AIDS mortality (Karonga and the Africa Centre), or
from mortality trends stratified by individual HIV status
(Masaka). In contrast, in Kisesa, the fall in all-cause
mortality was similar for HIV-positive and HIV-negative
women, while the evidence for different mortality trends in
HIV-positive and HIV-negative men was due partly to
increased mortality among HIV-negative men for which
there is no obvious explanation.
Our findings build on those already published from the
same DSS (Jahn et al. 2008; Herbst et al. 2009; Floyd et al.
2010), and are consistent with others that indicate a large
effect of ART provision on all-cause and AIDS mortality
(Reniers et al. 2009; Mwagomba et al. 2010). An impor-
tant strength of our new analysis is that it updates earlier
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Table 2 All-cause mortality among individuals aged 15–59 years old, by calendar time period
Kisesa Masaka Africa Centre Karonga
Deaths
Person
years*
Death
rate Deaths
Person
years
Death
rate Deaths
Person
years
Death
rate Deaths
Person
years
Death
rate
ART period
Pre-ART 528 58.0 9.1 390 35.6 11.0 2484 133.5 18.6 288 28.3 10.2
ART period 1 100 12.7 7.9 71 7.7 9.2 1280 67.4 19.0 158 18.5 8.5
ART period 2 245 34.3 7.2 225 33.7 6.7 2066 139.9 14.8 296 50.2 5.9
Sex
Male
Pre-ART 263 28.4 9.3 185 17.2 10.8 1204 57.2 21.0 130 13.5 9.6
ART period 1 51 6.2 8.2 34 3.7 9.3 568 28.7 19.8 84 8.8 9.5
ART period 2 136 16.3 8.3 109 15.9 6.9 998 59.6 16.7 153 23.8 6.4
Female
Pre-ART 265 29.6 9.0 205 18.5 11.1 1280 76.2 16.8 158 14.8 10.7
ART period 1 49 6.5 7.5 37 4.0 9.2 712 38.7 18.4 74 9.7 7.6
ART period 2 109 17.9 6.1 116 17.7 6.5 1068 80.3 13.3 143 26.5 5.4
Age (years)
15–29
Pre-ART 145 31.4 4.6 109 20.5 5.3 730 76.2 9.6 59 16.4 3.6
ART period 1 30 6.8 4.4 21 4.3 4.9 351 39.0 9.0 31 10.6 2.9
ART period 2 59 16.5 3.6 67 18.0 3.7 556 80.7 6.9 64 28.0 2.3
30–44
Pre-ART 238 18.1 13.2 192 9.9 19.5 1156 37.0 31.2 147 7.9 18.7
ART period 1 45 4.1 11.0 34 2.3 15.0 599 17.5 34.3 79 5.4 14.7
ART period 2 106 11.3 9.4 84 10.1 8.4 848 35.6 23.8 138 15.3 9.1
45–59
Pre-ART 145 8.4 17.2 89 5.3 16.7 598 20.2 29.6 82 4.0 20.4
ART period 1 25 1.9 13.3 16 1.2 13.5 330 11.0 30.1 48 2.5 19.0
ART period 2 80 6.5 12.3 74 5.6 13.2 662 23.6 28.1 94 7.0 13.4
Area of residence
Remote rural
Pre-ART 254 30.3 8.4 1399 79.5 17.6 93 13.5 6.9
ART period 1 48 6.5 7.3 672 39.2 17.1 73 9.6 7.6
ART period 2 142 18.9 7.5 1108 77.7 14.3 134 26.3 5.1
Urban
Pre-ART 105 9.3 11.3
ART period 1 51 4.2 12.3
ART period 2 142 12.2 11.6
Rural, roadside ⁄ peri-urban
Pre-ART 274 27.7 9.9 903 42.7 21.1 195 14.8 13.2
ART period 1 52 6.2 8.4 456 21.0 21.7 85 8.9 9.5
ART period 2 103 15.3 6.7 685 42.7 16.0 162 24.0 6.8
ART, antiretroviral therapy; DSS, demographic surveillance sites.
*Person-years are in units of 1000, for example 58.0 is 58 000 person-years. Table includes all adults aged 15–59 years old in the analysis,
irrespective of whether HIV status is known.
Death rate is per 1000 person-years.
For the Africa Centre, ‘urban’ is defined as areas proclaimed as such by the district municipality; ‘peri-urban’ areas are areas of informal
settlement with a population density in excess of 400 persons per km2; ‘rural’ areas are the remaining parts of the surveillance area
with scattered homesteads and a population density of <400 persons per km2. High density settlements (peri-urban) are generally
surrounding existing urban areas, or along larger roads in the area. The Masaka DSS is in a very rural area, and so no distinctions
were made according to area of residence, while the Karonga and Kisesa DSS have no urban areas.
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Table 3 All-cause mortality among individuals aged 15–59 years old, by calendar time period and stratified by individual HIV status,
Kisesa and Masaka DSS
HIV-negative HIV-positive
Deaths
Person
years
Death
rate
Crude
RR 95% CI Deaths
Person
years
Death
rate
Crude
RR 95% CI
(a) Masaka
ART period
Pre-ART 100 26.6 3.8 215 2.0 108.2
ART period 1 23 6.1 3.8 1.00 0.63–1.57 38 0.5 81.8 0.76 0.54–1.07
ART period 2 91 26.1 3.5 0.93 0.70–1.23 86 2.3 37.8 0.35 0.27–0.45
Sex
Male
Pre-ART 55 12.6 4.4 1 98 0.8 116.3 1
ART period 1 11 2.9 3.8 0.88 0.46–1.67 16 0.2 86.5 0.74 0.44–1.26
ART period 2 47 12.1 3.9 0.89 0.60–1.31 39 0.9 45.6 0.39 0.27–0.57
Female
Pre-ART 45 13.9 3.2 1 117 1.1 102.2 1
ART period 1 12 3.2 3.7 1.15 0.61–2.17 22 0.3 78.7 0.77 0.49–1.21
ART period 2 44 13.9 3.2 0.98 0.65–1.48 47 1.4 33.1 0.32 0.23–0.45
Age (years)
15–29
Pre-ART 35 15.7 2.2 1 52 0.7 71.4 1
ART period 1 8 3.5 2.3 1.02 0.47–2.20 10 0.2 63.6 0.89 0.45–1.75
ART period 2 30 14.6 2.1 0.92 0.57–1.50 21 0.6 33.2 0.46 0.28–0.77
30–44
Pre-ART 33 6.8 4.9 1 121 1.0 121.0 1
ART period 1 4 1.6 2.4 0.5 0.18–1.41 25 0.3 99.5 0.82 0.53–1.26
ART period 2 23 7.1 3.2 0.66 0.39–1.13 39 1.2 31.5 0.26 0.18–0.37
45–59
Pre-ART 32 4.1 7.8 1 42 0.3 161.7 1
ART period 1 11 1.0 11.5 1.46 0.74–2.90 3 0.1 53.7 0.33 0.10–1.07
ART period 2 38 4.4 8.7 1.11 0.70–1.78 26 0.4 64.0 0.4 0.24–0.65
(b) Kisesa
ART Period
Pre-ART 149 29.2 5.1 128 2.1 62.1
ART period 1 36 6.4 5.6 1.10 0.76–1.58 22 0.5 48.1 0.77 0.49–1.22
ART period 2 118 23.0 5.1 1.01 0.79–1.28 71 1.7 43.0 0.69 0.52–0.93
Sex
Male
Pre-ART 63 13.6 4.6 1 63 0.9 71.4 1
ART period 1 20 3.0 6.8 1.46 0.88–2.41 10 0.2 51.3 0.72 0.37–1.40
ART period 2 70 10.7 6.6 1.42 1.01–1.99 34 0.6 54.3 0.76 0.50–1.15
Female
Pre-ART 86 15.6 5.5 1 65 1.2 55.2 1
ART period 1 16 3.5 4.6 0.84 0.49–1.43 12 0.3 45.7 0.83 0.45–1.53
ART period 2 48 12.4 3.9 0.71 0.50–1.01 37 1.0 36.1 0.66 0.44–0.98
Age (years)
15–29
Pre-ART 27 13.9 1.9 1 29 0.8 35.3 1
ART period 1 10 3.1 3.3 1.68 0.81–3.46 6 0.2 37.0 1.05 0.44–2.52
ART period 2 32 11.1 2.9 1.49 0.90–2.49 12 0.5 26.6 0.75 0.38–1.47
30–44
Pre-ART 57 10.3 5.6 1 68 1.0 71.2 1
ART period 1 15 2.2 6.8 1.22 0.69–2.15 9 0.2 39.8 0.56 0.28–1.12
ART period 2 42 7.4 5.7 1.02 0.68–1.51 40 0.9 45.7 0.64 0.43–0.95
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Table 3 (Continued)
HIV-negative HIV-positive
Deaths
Person
years
Death
rate
Crude
RR 95% CI Deaths
Person
years
Death
rate
Crude
RR 95% CI
45–59
Pre-ART 65 5.1 12.9 1 31 0.3 108.7 1
ART period 1 11 1.1 9.6 0.75 0.39–1.41 7 0.1 100.8 0.93 0.41–2.10
ART period 2 44 4.6 9.7 0.75 0.51–1.10 19 0.3 58.7 0.54 0.31–0.96
Area of residence
Remote rural
Pre-ART 89 18.4 4.9 1 57 1.0 58.2 1
ART period 1 15 3.7 4.1 0.84 0.49–1.45 9 0.2 42.0 0.72 0.36–1.46
ART period 2 77 13.4 5.7 1.18 0.87–1.61 32 0.8 41.3 0.71 0.46–1.10
Rural, roadside
Pre-ART 60 10.9 5.5 1 71 1.1 65.7 1
ART period 1 21 2.8 7.6 1.38 0.84–2.27 13 0.2 53.5 0.81 0.45–1.47
ART period 2 41 9.6 4.3 0.77 0.52–1.15 39 0.9 44.5 0.68 0.46–1.00
ART, antiretroviral therapy.
Table 4 AIDS and non-AIDS mortality among individuals aged 15–59 years old, by calendar time period, Karonga and Africa Centre DSS
Non-AIDS mortality AIDS mortality*
Deaths
Person
years
Death
rate
Crude
RR 95% CI Deaths
Person
years
Death
rate
Crude
RR 95% CI
(a) Karonga
ART period
Pre-ART 108 28.32 3.81 180 28.32 6.36
ART period 1 71 18.52 3.83 1.01 0.75–1.36 87 18.52 4.7 0.74 0.57–0.95
ART period 2 181 50.24 3.61 0.95 0.75–1.20 115 50.24 2.29 0.36 0.29–0.46
Sex
Male
Pre-ART 63 13.5 4.7 1 67 13.49 5.0 1
ART period 1 41 8.8 4.7 1 0.67–1.48 43 8.81 4.9 0.98 0.67–1.44
ART period 2 92 23.8 3.9 0.83 0.60–1.14 61 23.76 2.6 0.52 0.37–0.73
Female
Pre-ART 45 14.8 3.0 1 113 14.83 7.6 1
ART period 1 30 9.7 3.1 1.02 0.64–1.62 44 9.71 4.5 0.59 0.42–0.84
ART period 2 89 26.5 3.4 1.11 0.77–1.59 54 26.48 2.0 0.27 0.19–0.37
Age (years)
15–29
Pre-ART 26 16.4 1.6 1 33 16.42 2.0 1
ART period 1 17 10.6 1.6 1.01 0.55–1.86 14 10.61 1.3 0.66 0.35–1.23
ART period 2 53 28.0 1.9 1.2 0.75–1.91 11 27.96 0.4 0.2 0.10–0.39
30–44
Pre-ART 45 7.9 5.7 1 102 7.88 12.9 1
ART period 1 31 5.4 5.8 1.01 0.64–1.59 48 5.38 8.9 0.69 0.49–0.97
ART period 2 70 15.3 4.6 0.8 0.55–1.17 68 15.25 4.5 0.34 0.25–0.47
45–59
Pre-ART 37 4.0 9.2 1 45 4.02 11.2 1
ART period 1 23 2.5 9.1 0.99 0.59–1.66 25 2.53 9.9 0.88 0.54–1.44
ART period 2 58 7.0 8.3 0.9 0.59–1.35 36 7.03 5.1 0.46 0.30–0.71
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Table 4 (Continued)
Non-AIDS mortality AIDS mortality*
Deaths
Person
years
Death
rate
Crude
RR 95% CI Deaths
Person
years
Death
rate
Crude
RR 95% CI
Area of residence
Remote rural
Pre-ART 36 13.49 2.67 1 57 13.49 4.22 1
ART period 1 39 9.6 4.06 1.52 0.97–2.40 34 9.6 3.54 0.84 0.55–1.28
ART period 2 82 26.25 3.12 1.17 0.79–1.73 52 26.25 1.98 0.47 0.32–0.68
Rural, roadside
Pre-ART 72 14.83 4.86 1 123 14.83 8.29 1
ART period 1 32 8.92 3.59 0.74 0.49–1.12 53 8.92 5.94 0.72 0.52–0.99
ART period 2 99 23.99 4.13 0.85 0.63–1.15 63 23.99 2.63 0.32 0.23–0.43
(b) Africa Centre
ART period
Pre-ART 670 133.5 5.0 1 1814 133.45 13.6 1
ART period 1 379 67.4 5.6 1.12 0.99–1.27 901 67.39 13.4 0.98 0.91–1.07
ART period 2 679 139.9 4.9 0.97 0.87–1.08 1387 139.91 9.9 0.73 0.68–0.78
Sex
Male
Pre-ART 402 57.2 7.0 1 802 57.24 14.0 1
ART period 1 203 28.7 7.1 1.01 0.85–1.19 365 28.69 12.7 0.91 0.80–1.03
ART period 2 376 59.6 6.3 0.90 0.78–1.03 622 59.6 10.4 0.74 0.67–0.83
Female
Pre-ART 268 76.2 3.5 1 1012 76.21 13.3 1
ART period 1 176 38.7 4.6 1.29 1.07–1.56 536 38.71 13.9 1.04 0.94–1.16
ART period 2 303 80.3 3.8 1.07 0.91–1.26 765 80.3 9.5 0.72 0.65–0.79
Age (years)
15–29
Pre-ART 184 76.2 2.4 1 546 76.22 7.2 1
ART period 1 121 39.0 3.1 1.29 1.02–1.62 230 38.97 5.9 0.82 0.71–0.96
ART period 2 214 80.7 2.7 1.10 0.90–1.34 342 80.7 4.2 0.59 0.52–0.68
30–44
Pre-ART 242 37.0 6.5 1 914 37.01 24.7 1
ART period 1 132 17.5 7.6 1.16 0.93–1.43 467 17.47 26.7 1.08 0.97–1.21
ART period 2 195 35.6 5.5 0.84 0.69–1.01 653 35.62 18.3 0.74 0.67–0.82
45–59
Pre-ART 244 20.2 12.1 1 354 20.22 17.5 1
ART period 1 126 11.0 11.5 0.95 0.77–1.18 204 10.96 18.6 1.06 0.90–1.26
ART period 2 270 23.6 11.5 0.95 0.80–1.13 392 23.59 16.6 0.95 0.82–1.10
Area of residence
Remote rural
Pre-ART 376 79.5 4.7 1 1023 79.45 12.9 1
ART period 1 199 39.2 5.1 1.07 0.90–1.27 473 39.23 12.1 0.94 0.84–1.04
ART period 2 378 77.7 4.9 1.03 0.89–1.19 730 77.67 9.4 0.73 0.66–0.80
Urban
Pre-ART 38 9.3 4.1 1 67 9.27 7.2 1
ART period 1 16 4.2 3.9 0.94 0.52–1.68 35 4.15 8.4 1.17 0.77–1.75
ART period 2 48 12.2 3.9 0.96 0.63–1.47 94 12.21 7.7 1.06 0.78–1.46
Peri-Urban
Pre-ART 244 42.7 5.7 1 659 42.72 15.4 1
ART period 1 135 21.0 6.4 1.13 0.91–1.39 321 21.01 15.3 0.99 0.87–1.13
ART period 2 208 42.7 4.9 0.85 0.71–1.03 477 42.71 11.2 0.72 0.64–0.81
ART, antiretroviral therapy; DSS, demographic surveillance sites.
*AIDS mortality rates are much lower than mortality rates in HIV-positive individuals, because the denominator is the total population
and not just those who are HIV-positive. This also explains the much higher mortality rates in the Africa Centre DSS than in the Karonga DSS,
because HIV prevalence is higher in the Africa Centre DSS than in the Karonga DSS.
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work and standardises methods and presentation of find-
ings across four DSS to enable fair comparison and
synthesis of findings.
The overall findings fit reasonably well with what is
known about ART uptake and retention in treatment
programmes in each site, and with what was known about
the population-attributable fraction (PAF) of all-cause
mortality because of AIDS prior to ART provision.
By multiplying together the pre-ART fraction of deaths
attributable to AIDS (f), the ART uptake as a proportion of
those in need of treatment (u) and retention in care – the
proportion alive and on treatment after 1 year (r), we can
approximate the proportion of deaths averted by the use
of ART (p). Symbolically, p  f · u · r.
In Karonga, 63% of deaths among 15–59 year olds
were attributed to AIDS prior to ART provision (Jahn
et al. 2008); ART uptake as a proportion of those in need
has been estimated to be at least 60% by 2008 (Wringe
et al. 2012), and among patients who first registered at
the ART clinic in the study area after January 2008,
retention in care at 12 months after starting ART was
88% (C. Mwafulirwa, unpublished data), giving an
approximate estimate of the proportion of deaths averted
by ART of 33% (=0.63 · 0.60 · 0.88), compared with an
observed fall of 42%.
For Masaka, the proportion of deaths attributable to
AIDS in the pre-ART era was 46% (Porter & Zaba 2004);
ART uptake was estimated to be at least 70% of those in
need by 2008 (Wringe et al. 2012); and retention in
care is 87% in Masaka at 12 months after starting ART
(P. Kazooba, unpublished data), so an approximate
estimate of the proportion of deaths averted by ART is
28% (=0.46 · 0.7 · 0.87), again somewhat lower than the
observed fall (39%).
In the Africa Centre DSS, 60% of deaths among
15–59 year olds were attributed to AIDS prior to ART
provision (Hosegood et al. 2004) – lower than in Karonga
despite much higher HIV prevalence, probably because the
mortality rate for non-HIV-related causes of death is
higher. The percentage of HIV-positive individuals in need
of ART was 45% (Zaba et al. 2012), while 21% of HIV-
positive individuals were on ART in 2008 (Cooke et al.
2010), so that uptake as a proportion of need was 47%
(=21 ⁄45). Assuming retention in care is 75%, then a very
approximate estimate of the proportion of deaths averted
by ART would be 21% (=0.60 · 0.47 · 0.75), similar
to the observed fall.
In contrast, in Kisesa, ART uptake was 3% of those
in need at the end of 2007, so ART provision cannot have
had much effect on population-level mortality.
In conclusion, our study provides strong evidence that
public-sector ART provision has brought substantial
reductions in adult mortality. The largest falls have
occurred where ART provision has been rapidly decentra-
lised (Karonga and the Africa Centre DSS) or where it has
been available locally (Masaka), suggesting that decen-
tralisation and ⁄or localisation of treatment provision are
important. There remains scope to increase uptake of ART
among individuals in need of treatment, and thus bring
even larger benefits in terms of lives saved.
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